BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34026620)

  • 1. The MicroRNA Landscape of MYCN-Amplified Neuroblastoma.
    Misiak D; Hagemann S; Bell JL; Busch B; Lederer M; Bley N; Schulte JH; Hüttelmaier S
    Front Oncol; 2021; 11():647737. PubMed ID: 34026620
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.
    Buechner J; Tømte E; Haug BH; Henriksen JR; Løkke C; Flægstad T; Einvik C
    Br J Cancer; 2011 Jul; 105(2):296-303. PubMed ID: 21654684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.
    Terrile M; Bryan K; Vaughan L; Hallsworth A; Webber H; Chesler L; Stallings RL
    PLoS One; 2011; 6(12):e28356. PubMed ID: 22164278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN regulates oncogenic MicroRNAs in neuroblastoma.
    Schulte JH; Horn S; Otto T; Samans B; Heukamp LC; Eilers UC; Krause M; Astrahantseff K; Klein-Hitpass L; Buettner R; Schramm A; Christiansen H; Eilers M; Eggert A; Berwanger B
    Int J Cancer; 2008 Feb; 122(3):699-704. PubMed ID: 17943719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.
    Haug BH; Henriksen JR; Buechner J; Geerts D; Tømte E; Kogner P; Martinsson T; Flægstad T; Sveinbjørnsson B; Einvik C
    Carcinogenesis; 2011 Jul; 32(7):1005-12. PubMed ID: 21572098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs.
    Haug BH; Hald ØH; Utnes P; Roth SA; Løkke C; Flægstad T; Einvik C
    Anticancer Res; 2015 May; 35(5):2521-30. PubMed ID: 25964525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
    Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
    Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
    Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells.
    Zhao Z; Ma X; Shelton SD; Sung DC; Li M; Hernandez D; Zhang M; Losiewicz MD; Chen Y; Pertsemlidis A; Yu X; Liu Y; Du L
    Oncotarget; 2016 Nov; 7(48):79372-79387. PubMed ID: 27764804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma.
    De Brouwer S; Mestdagh P; Lambertz I; Pattyn F; De Paepe A; Westermann F; Schroeder C; Schulte JH; Schramm A; De Preter K; Vandesompele J; Speleman F
    Int J Cancer; 2012 Jun; 130(11):2591-8. PubMed ID: 21796614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma.
    Beckers A; Van Peer G; Carter DR; Gartlgruber M; Herrmann C; Agarwal S; Helsmoortel HH; Althoff K; Molenaar JJ; Cheung BB; Schulte JH; Benoit Y; Shohet JM; Westermann F; Marshall GM; Vandesompele J; De Preter K; Speleman F
    Cancer Lett; 2015 Sep; 366(1):123-32. PubMed ID: 26123663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
    Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation.
    Beckers A; Van Peer G; Carter DR; Mets E; Althoff K; Cheung BB; Schulte JH; Mestdagh P; Vandesompele J; Marshall GM; De Preter K; Speleman F
    Oncotarget; 2015 Mar; 6(7):5204-16. PubMed ID: 25294817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
    Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
    Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
    Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
    Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.
    Zhang H; Liu T; Yi S; Gu L; Zhou M
    Mol Oncol; 2015 Aug; 9(7):1301-11. PubMed ID: 25864587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.
    Bray I; Bryan K; Prenter S; Buckley PG; Foley NH; Murphy DM; Alcock L; Mestdagh P; Vandesompele J; Speleman F; London WB; McGrady PW; Higgins DG; O'Meara A; O'Sullivan M; Stallings RL
    PLoS One; 2009 Nov; 4(11):e7850. PubMed ID: 19924232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.